{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:10:20Z","timestamp":1787505020934,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013845","name":"Fondation contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRCPJT\\\\100012"],"award-info":[{"award-number":["CRCPJT\\\\100012"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013945","name":"Les Laboratoires Servier SAS Institut de Recherches","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.104540","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:36:41Z","timestamp":1744209401000},"page":"104540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10\u2014Precision Medicine)"],"prefix":"10.1016","volume":"10","author":[{"given":"D.","family":"Malka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Borbath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Couch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Dewever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9935","key":"10.1016\/j.esmoop.2025.104540_bib1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104540_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/hpb.12444","article-title":"Gallbladder cancer: expert consensus statement","volume":"17","author":"Aloia","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"14","key":"10.1016\/j.esmoop.2025.104540_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2025.104540_bib4","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.3390\/jcm10143108","article-title":"Chemotherapy for biliary tract cancer in 2021","volume":"10","author":"Sasaki","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104540_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"Phelip","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104540_bib6","article-title":"SWOG 1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"41","author":"Shroff","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104540_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104540_bib8","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104540_bib9","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10391","key":"10.1016\/j.esmoop.2025.104540_bib10","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104540_bib11","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104540_bib12","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104540_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104540_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104540_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104540_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104540_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2025.104540_bib18","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.104540_bib19","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","article-title":"Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial","volume":"18","author":"Ohba","year":"2022","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104540_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104540_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2017.05.006","article-title":"Matching genomic molecular aberrations with molecular targeted agents: are biliary tract cancers an ideal playground?","volume":"81","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104540_bib22","volume":"38","author":"Borad","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.104540_bib23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2024.42.3_suppl.516","article-title":"PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion\/rearrangement","volume":"42","author":"Abou-Alfa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104540_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102049","article-title":"Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma","volume":"8","author":"Lamarca","year":"2023","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.esmoop.2025.104540_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104540_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104540_bib27","first-page":"GS1","article-title":"Abstract GS1-10: Clinical utility of molecular tumor profiling: results from the randomized trial SAFIR02-BREAST","volume":"82","author":"Andr\u00e9","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.104540_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1037439","article-title":"Design and analysis of umbrella trials: where do we stand?","volume":"9","author":"Ouma","year":"2022","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104540_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104540_bib30","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO Scale for Clinical Actionability of molecular Targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.104540_bib31","article-title":"Isocitrate dehydrogenase-mutated cholangiocarcinoma: natural history and clinical outcomes","volume":"6","author":"Wintheiser","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104540_bib32","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2023.41.16_suppl.4019","article-title":"Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial","volume":"41","author":"Crolley","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104540_bib33","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.104540_bib34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2023.41.4_suppl.610","article-title":"Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results","volume":"41","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104540_bib35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104540_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.104540_bib37","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104540_bib38","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1200\/JCO.23.02078","article-title":"Pertuzumab plus trastuzumab in patients with biliary tract cancer with ERBB2\/3 alterations: results from the targeted agent and profiling utilization registry study","volume":"42","author":"Cannon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104540_bib39","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"issue":"33","key":"10.1016\/j.esmoop.2025.104540_bib40","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104540_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104540_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600\u2013mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925004090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:43:58Z","timestamp":1762598638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925004090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925004090"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104540","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10\u2014Precision Medicine)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104540"}}